NovaBridge Biosciences stock: Visara secures YOL104-2 option

NovaBridge Biosciences is highlighting a new potential addition to its ophthalmology portfolio. On October 20, 2026, its majority-owned subsidiary Visara secured an exclusive option for the potential acquisition of YOL104-2, according to the NovaBridge Biosciences company website.

Option concerns investigational eye therapy

YOL104-2 is described as a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic. The candidate is being developed for ocular surface squamous neoplasia, a disease area within ophthalmology.

The company presents YOL104-2 as having potential first-in-class characteristics. The transaction is structured as an exclusive option for a potential acquisition, rather than a completed acquisition, leaving further development and ownership subject to subsequent steps.

Pipeline breadth matters for investors

For investors, the announcement adds another development program to Visara's ophthalmology activities. That broadens the strategic scope of NovaBridge's pipeline, although the value of the program remains dependent on clinical development, regulatory progress and any future exercise of the option.

Broader market developments can be followed in the current market reports.